Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

NCT01544595 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1147

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque-type Psoriasis

Interventions

DRUG: Secukinumab (AIN457)
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals